Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C20H24N2O2.C7H6O3 |
Molecular Weight | 462.5375 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)C1=C(O)C=CC=C1.[H][C@]2(C[C@@H]3CCN2C[C@@H]3C=C)[C@H](O)C4=C5C=C(OC)C=CC5=NC=C4
InChI
InChIKey=MAYUSTFJKJSJNC-DSXUQNDKSA-N
InChI=1S/C20H24N2O2.C7H6O3/c1-3-13-12-22-9-7-14(13)10-19(22)20(23)16-6-8-21-18-5-4-15(24-2)11-17(16)18;8-6-4-2-1-3-5(6)7(9)10/h3-6,8,11,13-14,19-20,23H,1,7,9-10,12H2,2H3;1-4,8H,(H,9,10)/t13-,14-,19-,20+;/m0./s1
Molecular Formula | C20H24N2O2 |
Molecular Weight | 324.4168 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Molecular Formula | C7H6O3 |
Molecular Weight | 138.1207 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Quinine soluble salts possess an extremely bitter taste, that may have a perplexing problem especially to children. That is why one of the most common combinations for oral administration is a slightly soluble quinine salicylate salt. It is known that now quinine is used in the absence of artemisin combination therapies (ARTs) to treat CQ resistant (CQR) P. falciparum malaria. Although the precise mechanism of the antimalarial activity of quinine is not completely understood, it can act via the inhibition on nucleic acid synthesis, on protein synthesis, and on glycolysis in Plasmodium falciparum, and also drug can affect via the binding with hemazoin in parasitized erythrocytes.
CNS Activity
Sources: https://pubmed.ncbi.nlm.nih.gov/3896000
Curator's Comment: The ratio of cerebrospinal fluid to free (unbound) plasma quinine was 0.55 /- 0.33 which suggests that quinine does not freely cross the blood-brain barrier.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: GO:0006096 Sources: https://pubmed.ncbi.nlm.nih.gov/20864177 |
|||
Target ID: GO:0090304 Sources: https://pubmed.ncbi.nlm.nih.gov/20864177 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative |
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT00540202
Quinine tablets given at 10mg/kg 8 hourly for 7 days
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://pubmed.ncbi.nlm.nih.gov/3048758
Prior to treatment, the in vitro susceptibility of isolates of P. falciparum to quinine was determined using the standardized procedure recommended by WHO. The minimum inhibitory concentration (MIC) was defined as the lowest concentration that completely inhibited schizont formation. The MICs for quinine (mean, 3.02 uM) were significantly greater.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:25:44 GMT 2023
by
admin
on
Fri Dec 15 15:25:44 GMT 2023
|
Record UNII |
6DY04L71DR
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
CFR |
21 CFR 310.547
Created by
admin on Fri Dec 15 15:25:44 GMT 2023 , Edited by admin on Fri Dec 15 15:25:44 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
6DY04L71DR
Created by
admin on Fri Dec 15 15:25:44 GMT 2023 , Edited by admin on Fri Dec 15 15:25:44 GMT 2023
|
PRIMARY | |||
|
DTXSID40996498
Created by
admin on Fri Dec 15 15:25:44 GMT 2023 , Edited by admin on Fri Dec 15 15:25:44 GMT 2023
|
PRIMARY | |||
|
CHEMBL170
Created by
admin on Fri Dec 15 15:25:44 GMT 2023 , Edited by admin on Fri Dec 15 15:25:44 GMT 2023
|
PRIMARY | |||
|
71794
Created by
admin on Fri Dec 15 15:25:44 GMT 2023 , Edited by admin on Fri Dec 15 15:25:44 GMT 2023
|
PRIMARY | |||
|
212-027-7
Created by
admin on Fri Dec 15 15:25:44 GMT 2023 , Edited by admin on Fri Dec 15 15:25:44 GMT 2023
|
PRIMARY | |||
|
100000078603
Created by
admin on Fri Dec 15 15:25:44 GMT 2023 , Edited by admin on Fri Dec 15 15:25:44 GMT 2023
|
PRIMARY | |||
|
1426899
Created by
admin on Fri Dec 15 15:25:44 GMT 2023 , Edited by admin on Fri Dec 15 15:25:44 GMT 2023
|
PRIMARY | RxNorm | ||
|
750-90-3
Created by
admin on Fri Dec 15 15:25:44 GMT 2023 , Edited by admin on Fri Dec 15 15:25:44 GMT 2023
|
PRIMARY | |||
|
SUB15094MIG
Created by
admin on Fri Dec 15 15:25:44 GMT 2023 , Edited by admin on Fri Dec 15 15:25:44 GMT 2023
|
PRIMARY | |||
|
6DY04L71DR
Created by
admin on Fri Dec 15 15:25:44 GMT 2023 , Edited by admin on Fri Dec 15 15:25:44 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE | |||
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY | |||
|
ACTIVE MOIETY |